XNAS · Healthcare · Biotechnology
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q4 2025 | -0.51 | -0.92 | -80.39% | $0 | ❌ Miss | -2.04% | +16.35% | +16.33% |
| 2025-11-26 | Q3 2025 | -0.54 | -0.33 | +38.89% | $0 | ✅ Beat | — | — | — |
| 2025-08-28 |
| Q2 2025 |
| -0.79 |
| -0.63 |
| +24.10% |
| $0 |
| ✅ Beat |
| +0.00% |
| -7.25% |
| +1.45% |
| 2024-11-14 | Q3 2024 | — | -2.31 | — | $0 | — | -5.48% | -9.68% | +5.48% |
| 2024-08-28 | Q2 2024 | — | -2.16 | — | $0 | — | -1.68% | -12.62% | +120.46% |
| 2024-05-30 | Q1 2024 | — | -2.76 | — | $0 | — | +1.65% | -3.60% | -22.25% |
| 2024-04-04 | Q4 2023 | -3.84 | -11.76 | -206.25% | $0 | ❌ Miss | +2.79% | +27.12% | +27.03% |
| 2023-11-22 | Q3 2023 | -3.60 | -2.88 | +20.00% | $0 | ✅ Beat | +7.68% | +18.93% | +41.73% |
Showing last 8 quarters.